Adagio raises a monster $336M round for bespoke COVID-19 drug battle

Adagio Therapeutics has nabbed a massive $336 million series C from a who’s who of investors as it more than triples its previous funding drive last year.

The company raised $50 million in its debut last year and $80 million in November; Now, as vaccines start to play a bigger part in global protection, there is still a major need for a bespoke treatment to help those who are still getting infected and reduce their risk of severe illness or death.